CUA 2017: Long-Term Incidence of Venous Thromboembolic Events Following cystectomy: A Population-Based Analysis

Toronto, Ontario (UroToday.com) Cancer and immobility both contribute to the development of venous thromboembolic events (VTE), including pulmonary embolism and deep vein thrombosis. As such, patients undergoing radical cystectomy for bladder cancer are at elevated risk. Dr. Diane Magee presented a study assessing the long-term incidence of VTE among all patients undergoing radical cystectomy in the province of Ontario.

The authors conducted a population-based cohort study to examine the incidence of VTE, a composite of pulmonary embolism and deep vein thrombosis, among all patients treated with radical cystectomy for bladder cancer between 2002 and 2014 in Ontario, Canada. The authors estimated the cumulative incidence of VTE and used Fine and Grey competing risk survival analysis to assess risk factors for VTE while accounting for the risk of any cause mortality.

Among 3623 eligible patients, the 10-year cumulative incidence of VTE was 6.68%. Among those who experienced VTE, the median time from surgery was 216 days (interquartile range 52‒677; mean 527); however, VTE rates peaked much earlier, with a mode of 20 days. Neither preoperative (hazard ratio [HR] 0.68, 95% confidence interval [CI] 0.39‒1.18), nor postoperative chemotherapy (HR 1.32, 95% CI 0.95‒1.84) were significantly associated with VTE incidence. While patients with a prior history of VTE had increased risk of VTE after cystectomy (HR 5.1, 95% CI 2.2‒12.0), age, gender, comorbidity score, rurality, diversion type (continent vs. ileal conduit), treatment at an academic institution, or year of treatment were not significantly associated with the risk of VTE.

In summary, among patients undergoing cystectomy for bladder cancer, the cumulative incidence of VTE continues to rise long after the date of surgery, but the vast majority occur in the first postoperative year. Importantly, receipt of neoadjuvant or adjuvant chemotherapy was not associated with the incidence of VTE.

Presented By: Diana E. Magee, University of Toronto, Toronto, Ontario

Written By: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre  Twitter: @GoldbergHanan at the  72nd Canadian Urological Association Annual Meeting - June 24 - 27, 2017 - Toronto, Ontario, Canada
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe